Drugs that contain Fedratinib Hydrochloride

1. Drug name - INREBIC

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7528143 IMPACT Bi-aryl meta-pyrimidine inhibitors of kinases
Dec, 2026

(4 years from now)

US7825246 IMPACT Bi-aryl meta-pyrimidine inhibitors of kinases
Dec, 2026

(4 years from now)

CN103626742B IMPACT Connection-Aryl-Pyrimidine Inhibitor Of Kinase
Oct, 2026

(4 years from now)

CN101370792A IMPACT Bi-Aryl Meta-Pyrimidine Inhibitors Of Kinases
Oct, 2026

(4 years from now)

CN103626742A IMPACT -Aryl Pyrimidine-Inhibitor-Linked Kinase
Oct, 2026

(4 years from now)

CN101370792B IMPACT -Aryl Pyrimidine-Inhibitor-Linked Kinase
Oct, 2026

(4 years from now)

IN200802704P4 IMPACT Bi-Aryl Meta-Pyramidine Inhibitors Of Kinases
Oct, 2026

(4 years from now)

IN288239B IMPACT Bi-Aryl Metapyramidine Inhibitors Of Kinases
Oct, 2026

(4 years from now)

EP1951684B1 IMPACT Bi-Aryl Meta-Pyrimidine Inhibitors Of Kinases
Oct, 2026

(4 years from now)

EP1951684A1 IMPACT Bi-Aryl Meta-Pyrimidine Inhibitors Of Kinases
Oct, 2026

(4 years from now)

EP1951684A4 IMPACT Bi-Aryl Meta-Pyrimidine Inhibitors Of Kinases
Oct, 2026

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8138199 IMPACT Use of bi-aryl meta-pyrimidine inhibitors of kinases Jun, 2028

(5 years from now)

US10391094 IMPACT Compositions and methods for treating myelofibrosis Jun, 2032

(9 years from now)

Treatment: Treatment of adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 100MG BASE CAPSULE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.